Statistical shape modeling of the hip and the association with hip osteoarthritis: a systematic review

M. M.A. van Buuren*, N. K. Arden, S. M.A. Bierma-Zeinstra, W. M. Bramer, N. C. Casartelli, D. T. Felson, G. Jones, N. E. Lane, C. Lindner, N. A. Maffiuletti, J. B.J. van Meurs, A. E. Nelson, M. C. Nevitt, P. L. Valenzuela, J. A.N. Verhaar, H. Weinans, R. Agricola

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

8 Citations (Scopus)
2 Downloads (Pure)

Abstract

Objective: To summarize available evidence on the association between hip shape as quantified by statistical shape modeling (SSM) and the incidence or progression of hip osteoarthritis. Design: We conducted a systematic search of five electronic databases, based on a registered protocol (available: PROSPERO CRD42020145411). Articles presenting original data on the longitudinal relationship between radiographic hip shape (quantified by SSM) and hip OA were eligible. Quantitative meta-analysis was precluded because of the use of different SSM models across studies. We used the Newcastle–Ottawa Scale (NOS) for risk of bias assessment. Results: Nine studies (6,483 hips analyzed with SSM) were included in this review. The SSM models used to describe hip shape ranged from 16 points on the femoral head to 85 points on the proximal femur and hemipelvis. Multiple hip shape features and combinations thereof were associated with incident or progressive hip OA. Shape variants that seemed to be consistently associated with hip OA across studies were acetabular dysplasia, cam morphology, and deviations in acetabular version (either excessive anteversion or retroversion). Conclusions: Various radiographic, SSM-defined hip shape features are associated with hip OA. Some hip shape features only seem to increase the risk for hip OA when combined together. The heterogeneity of the used SSM models across studies precludes the estimation of pooled effect sizes. Further studies using the same SSM model and definition of hip OA are needed to allow for the comparison of outcomes across studies, and to validate the found associations.

Original languageEnglish
Pages (from-to)607-618
Number of pages12
JournalOsteoarthritis and Cartilage
Volume29
Issue number5
Early online date15 Dec 2020
DOIs
Publication statusPublished - 1 May 2021

Bibliographical note

Funding Information:
Within the submitted work: MvB reports a research grant from the Dutch Arthritis Society ( 18-2-203 ). CL reports a research grant from the Medical Research Council, UK ( MR/S00405X/1 ). MN reports a research grant from NIH . HW reports a research grant from the European Union .

Funding Information:
Outside the submitted work: NA reports personal fees from Pfizer and Eli Lilly and Company , with research grants from Merck . SBZ reports personal fees from Pfizer and Osteoarthritis and Cartilage, with research grants from the European Union , The Netherlands Organisation for Health Research and Development , the Dutch Arthritis Society , and Foreum . GJ reports personal fees from BMS , Roche , Abbvie , Amgen , Eli Lilly and Company , Novartis , Janssen , with research grants from Covance . AN reports personal fees from GSK , Flexion Therapeutics , MedScape and Health Press Ltd . HW reports research grants from the European Union , the Dutch Arthritis Society , and the Dutch Government . RA reports a research grant from the Dutch Arthritis Society .

Funding Information:
Within the submitted work: MvB reports a research grant from the Dutch Arthritis Society (18-2-203). CL reports a research grant from the Medical Research Council, UK (MR/S00405X/1). MN reports a research grant from NIH. HW reports a research grant from the European Union.Outside the submitted work: NA reports personal fees from Pfizer and Eli Lilly and Company, with research grants from Merck. SBZ reports personal fees from Pfizer and Osteoarthritis and Cartilage, with research grants from the European Union, The Netherlands Organisation for Health Research and Development, the Dutch Arthritis Society, and Foreum. GJ reports personal fees from BMS, Roche, Abbvie, Amgen, Eli Lilly and Company, Novartis, Janssen, with research grants from Covance. AN reports personal fees from GSK, Flexion Therapeutics, MedScape and Health Press Ltd. HW reports research grants from the European Union, the Dutch Arthritis Society, and the Dutch Government. RA reports a research grant from the Dutch Arthritis Society.

Publisher Copyright:
© 2020 The Authors

Fingerprint

Dive into the research topics of 'Statistical shape modeling of the hip and the association with hip osteoarthritis: a systematic review'. Together they form a unique fingerprint.

Cite this